Cargando…

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase whose proliferative effects can contribute to the development of many types of solid tumors when overexpressed. For this reason, EGFR inhibitors such as cetuximab can play an important role in treating cancers such as colorect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goulet, Dennis R., Chatterjee, Soumili, Lee, Wai-Ping, Waight, Andrew B., Zhu, Yi, Mak, Amanda Nga-Sze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788544/ https://www.ncbi.nlm.nih.gov/pubmed/35076451 http://dx.doi.org/10.3390/antib11010006

Ejemplares similares

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern
por: Tsai, Tsung-I, et al.
Publicado: (2022)

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
por: Yang, Guang, et al.
Publicado: (2021)

Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
por: Qian, Yichun, et al.
Publicado: (2014)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis
por: Valverde, Araceli, et al.
Publicado: (2017)

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer
por: Luo, Maochao, et al.
Publicado: (2021)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Reade, Chad A, et al.
Publicado: (2009)

Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab
por: Liu, Shujie, et al.
Publicado: (2022)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
por: Bonner, James A., et al.
Publicado: (2015)

ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
por: Kol, Arjan, et al.
Publicado: (2017)

Boosting of the enhanced permeability and retention effect with nanocapsules improves the therapeutic effects of cetuximab
por: Yang, Chao, et al.
Publicado: (2020)

Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
por: He, Xuzhi, et al.
Publicado: (2018)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab
por: Sun, Chaonan, et al.
Publicado: (2017)

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
por: Khalili, Jahan S., et al.
Publicado: (2020)

Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance
por: Wang, Yuetong, et al.
Publicado: (2016)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer
por: Nair, Sindhu, et al.
Publicado: (2020)

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Mu, Lan, et al.
Publicado: (2022)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR/SphK1 crosstalk
por: Schiefler, Carlotta, et al.
Publicado: (2014)

Transgenic goats producing an improved version of cetuximab in milk
por: Laible, Götz, et al.
Publicado: (2020)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab
por: Santis, Rita De, et al.
Publicado: (2014)

RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src
por: Zhang, Xiaomeng, et al.
Publicado: (2017)

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab
por: Froelich, Matthias F., et al.
Publicado: (2018)

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
por: Zhang, Keqiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i85j0q4eh3523f7k5975jsghui